UnitedHealth Group Incorporated (UNH Quick QuoteUNH - Free Report) continues to go through a turbulent phase while navigating rising medical costs, regulatory scrutiny and shifting industry dynamics. For investors accustomed to UnitedHealth’s consistent growth trajectory, the continued weakness has raised an important question: Are there deeper structural concerns, or is it simply a temporary setback for one of healthcare’s largest platforms?

The latest labor market data has added another layer of uncertainty. Healthcare employment unexpectedly declined in February, highlighting stress points within a sector that has historically been a reliable source of job creation. While the data does not directly determine insurer performance, it underscores the evolving landscape in which UnitedHealth operates. At the same time, the company’s stock has softened in recent months, reflecting a mix of macroeconomic volatility and company-specific pressures.

Healthcare Hiring Slowdown Adds to Sector Concerns

The U.S. healthcare industry rarely experiences employment contractions, making February’s decline notable. According to the U.S. Bureau of Labor Statistics, the broader economy shed more than 92,000 jobs during the month, including roughly 28,000 positions in healthcare. A strike involving workers at Kaiser Permanente played a major role in the decline. Even so, the data signals mounting pressure across healthcare systems, many of which are grappling with reimbursement challenges and evolving care models.

The national unemployment rate ticked up to 4.4% compared with 4.3% recorded in January. For health insurers, these dynamics can ultimately influence claims patterns, provider pricing and overall cost structures.

Market Rotation and Stock Weakness

UnitedHealth’s recent share decline has unfolded against a backdrop of shifting market leadership. Over the past three months, the stock has dropped 12.8%, underperforming the broader industry’s 10.1% decline. Some competitors have fared differently. Shares of Molina Healthcare, Inc. (MOH Quick QuoteMOH - Free Report) have slipped roughly 10% over the same period, while Centene Corporation (CNC Quick QuoteCNC - Free Report) has climbed nearly 13%. Meanwhile, the S&P 500 has declined about 2.5%.

Price Performance – UNH, MOH, CNC, Industry & S&P 500

Image Source: Zacks Investment Research

Part of UnitedHealth’s weakness reflects a broader investor rotation toward high-growth technology companies tied to artificial intelligence. As capital flows toward these themes, traditionally defensive sectors like healthcare have temporarily taken a back seat.

Geopolitical developments have also added to market volatility. Rising tensions involving Iran have contributed to higher energy prices and renewed inflation concerns, prompting investors to rebalance portfolios toward sectors expected to have stronger near-term momentum.

Operational Headwinds Come Into Focus

Beyond macro forces, UnitedHealth is confronting several internal challenges. One key metric illustrating the pressure is the company’s adjusted medical care ratio (MCR), which rose to 88.9% in 2025, representing a deterioration of 340 basis points from the previous year. The increase reflects higher utilization of healthcare services, particularly among seniors enrolled in government-supported programs.

Legal and regulatory scrutiny has also intensified. The U.S. Department of Justice is examining aspects of the company’s Medicare billing practices and the competitive conduct of Optum Rx, its pharmacy benefit management division. Such investigations increase headline risk and may result in additional compliance costs or operational changes.

The aftermath of the 2024 cyberattack involving Change Healthcare remains another source of uncertainty. Questions surrounding financial assistance to healthcare providers affected by the incident continue to draw regulatory attention.

Operational trends also reveal some softness in membership. The company expects total medical enrollment to range between 46.945 million and 47.495 million in 2026, down from 49.760 million in 2025. Declines are expected across several segments, including commercial risk plans, Medicare Advantage and Medicaid programs.

Adding to the pressure, federal regulators proposed only a modest 0.09% increase in Medicare Advantage payment rates for 2027. Given that Medicare Advantage represents a substantial share of UnitedHealthcare’s revenue base, reimbursement decisions are expected to affect profitability.

Structural Strengths Remain Intact

Despite these challenges, the company’s long-term strategic position remains intact. UnitedHealth operates one of the most comprehensive healthcare ecosystems in the industry, combining insurance operations with a broad healthcare services platform through Optum.

This integrated model enables the company to operate across multiple parts of the healthcare value chain, including insurance coverage, pharmacy benefit management, data analytics and direct care delivery. By coordinating services across these areas, UNH is expected to manage costs more effectively.

Capital distribution also remains disciplined. In 2025, the company returned nearly $7.9 billion to its shareholders through dividends and repurchased approximately $5.5 billion of stock. Management plans $2.5 billion in buybacks and about $8 billion in dividend payments for 2026 while maintaining balance-sheet flexibility.

Long-term demographic trends further reinforce UNH’s outlook. An aging population and rising prevalence of chronic diseases are expected to drive sustained demand for healthcare services and insurance coverage, particularly within government-supported programs serving senior citizens.

Where Do the Estimates Stand?

The Zacks Consensus Estimate for 2026 EPS is pegged at $17.70, indicating an 8.3% year-over-year improvement. The consensus estimate for revenues is pegged at $440.4 billion, implying a 1.6% decline from a year ago.

For 2027, EPS is projected to grow to $19.83, marking a 12.1% improvement. It has witnessed one upward estimate revision in the past month, against no downward movements. Revenues are pegged at $457.5 billion, 3.9% growth from a year ago.

Over the past four quarters, the company has missed estimates twice and beat twice, producing an average earnings surprise of negative 2.4%.

UNH’s Valuation

The continued selloff has pushed valuation below the historical average. The stock now trades at a forward price-to-earnings (P/E) ratio of 15.84X, below its five-year median of 19.29X. However, it is still above the industry average of 13.81X. In comparison, Molina and Centene are currently trading at 18.88X and 13.66X, respectively.

Image Source: Zacks Investment Research

Conclusion

UnitedHealth’s recent decline reflects a convergence of sector pressures, regulatory scrutiny and shifting market sentiment. Rising medical utilization, reimbursement uncertainty and membership softness are real challenges that could weigh on near-term performance. The recent decline in healthcare employment, although significantly influenced by temporary disruptions, adds another signal that the sector is entering a more complex operating phase.

At the same time, the company’s diversified healthcare platform, strong capital allocation and exposure to long-term demographic tailwinds continue to support its strategic positioning. The pullback in valuation suggests that some of the risks are already reflected in the share price. While the long-term outlook remains intact, near-term uncertainty argues for a more cautious stance. As a result, the stock presently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.